ATOS Atossa Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ATOS

Price (delayed)

$1.53

Market cap

$191.72M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.24

Enterprise value

$103.15M

Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and ...

Highlights
The quick ratio has declined by 38% since the previous quarter and by 15% year-on-year
The company's equity fell by 23% YoY and by 7% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://atossatherapeutics.com
Peers: JNJ LH DGX ENZ

Key stats

What are the main financial stats of ATOS
Market
Shares outstanding
125.3M
Market cap
$191.72M
Enterprise value
$103.15M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.11
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$30.09M
EBITDA
-$30.07M
Free cash flow
-$20.96M
Per share
EPS
-$0.24
Free cash flow per share
-$0.17
Book value per share
$0.73
Revenue per share
$0
TBVPS
$0.76
Balance sheet
Total assets
$96.25M
Total liabilities
$5.24M
Debt
$0
Equity
$91.02M
Working capital
$86.98M
Liquidity
Debt to equity
0
Current ratio
17.61
Quick ratio
16.92
Net debt/EBITDA
2.95
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-28.5%
Return on equity
-29.5%
Return on invested capital
-567.5%
Return on capital employed
-33.1%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ATOS stock price

How has the Atossa Therapeutics stock price performed over time
Intraday
0.66%
1 week
11.68%
1 month
-15%
1 year
153.1%
YTD
73.86%
QTD
-15%

Financial performance

How have Atossa Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$31.38M
Net income
-$30.09M
Gross margin
N/A
Net margin
N/A
The operating income fell by 13% YoY and by 2.9% QoQ
The net income has contracted by 12% YoY

Growth

What is Atossa Therapeutics's growth rate over time

Valuation

What is Atossa Therapeutics stock price valuation
P/E
N/A
P/B
2.11
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS fell by 14% YoY
ATOS's P/B is 92% above its last 4 quarters average of 1.1 and 17% above its 5-year quarterly average of 1.8
The company's equity fell by 23% YoY and by 7% QoQ

Efficiency

How efficient is Atossa Therapeutics business performance
The ROA has decreased by 38% YoY and by 8% from the previous quarter
The return on equity has declined by 38% year-on-year and by 7% since the previous quarter
ATOS's return on invested capital is down by 22% since the previous quarter and by 13% year-on-year

Dividends

What is ATOS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ATOS.

Financial health

How did Atossa Therapeutics financials performed over time
Atossa Therapeutics's total liabilities has surged by 52% QoQ but it has decreased by 6% YoY
Atossa Therapeutics's current ratio has decreased by 38% from the previous quarter and by 17% YoY
ATOS's debt is 100% smaller than its equity
The company's equity fell by 23% YoY and by 7% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.